Improved harmonization of eosin-5-maleimide binding test across different instruments and age groups

Area of Science:

• Hematology
• Clinical Cytometry
• Diagnostic Immunology

Background:

• The eosin-5'maleimide (EMA) binding test is a key diagnostic tool for hereditary spherocytosis (HS).
• Its performance is often compared against traditional osmotic fragility and cryohemolysis tests.
• Analysis of mean channel fluorescence (MCF) and coefficient of variation (CV) aids in HS identification.

Purpose of the Study:

• To evaluate the utility of the EMA binding test in detecting hereditary spherocytosis.
• To assess the impact of age on EMA test parameters (MCF and CV).
• To introduce and validate a novel "footprint" parameter for improved standardization.

Main Methods:

• Compared EMA binding test results in 65 normal controls (adults and newborns) and 12 HS cases.
• Utilized mean channel fluorescence (MCF) and coefficient of variation (CV) analysis.
• Introduced a side scatter (SSC) vs. EMA fluorescence "footprint" gate to define normal erythrocyte populations.

Main Results:

• Newborns exhibited higher MCF and CV values compared to adults, indicating age-related differences.
• The "footprint" parameter demonstrated high concordance (99.5%) for normal samples across age groups after normalization.
• Reduced band 3 protein in HS erythrocytes was associated with appearance outside the defined "footprint".

Conclusions:

• The "footprint" parameter enhances the standardization and implementation of the EMA binding test.
• This approach facilitates consistent application of the test across diverse age demographics.
• Improved standardization supports more reliable diagnosis of hereditary spherocytosis using the EMA test.